Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies

Summary of the activity of each major category of revenue allowance

For the three months ended September 30, 2012

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2012	$	7,063		$	4,436		$	5,540		$	—		$	17,039
Actual credits issued related to sales recorded in prior fiscal years	(6,504		)	(3,743		)	(875		)	(55		)	(11,177		)
Reserves or (reversals) charged during Fiscal 2013 related to sales in prior fiscal years	(372		)	105			—			55			(212		)
Reserves charged to net sales during Fiscal 2013 related to sales recorded in Fiscal 2013	19,350			5,675			1,405			139			26,569
Actual credits issued related to sales recorded in Fiscal 2013	(11,490		)	(2,277		)	—			(139		)	(13,906		)
Reserve Balance as of September 30, 2012	$	8,047		$	4,196		$	6,070		$	—		$	18,313

For the three months ended September 30, 2011

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2011	$	5,497		$	2,925		$	5,142		$	—		$	13,564
Actual credits issued related to sales recorded in prior fiscal years	(5,262		)	(2,686		)	(1,412		)	(92		)	(9,452		)
Reserves or (reversals) charged during Fiscal 2012 related to sales in prior fiscal years	(36		)	72			—			92			128
Reserves charged to net sales during Fiscal 2012 related to sales recorded in Fiscal 2012	17,477			4,358			1,337			202			23,374
Actual credits issued related to sales recorded in Fiscal 2012	(11,119		)	(1,943		)	—			(202		)	(13,264		)
Reserve Balance as of September 30, 2011	$	6,557		$	2,726		$	5,067		$	—		$	14,350

Summary of the activity of reserves for each of the major category of revenue allowance

	September 30,				June 30,
(In thousands)	2012		%		2012		%
Chargeback reserve	$	8,047	44	%	$	7,063	41	%
Rebate reserve	4,196		23	%	4,436		26	%
Return reserve	6,070		33	%	5,540		33	%
Other reserve	—		—	%	—		—	%
	$	18,313	100	%	$	17,039	100	%

Summary of net product sales by medical indication

(In thousands)	For the Three Months Ended September 30,
Medical Indication	2012		2011
Migraine Headache	$	1,249	$	1,612
Glaucoma	1,373		1,032
Gallstone Prevention	1,578		1,300
Cardiovascular	7,100		2,510
Thyroid Deficiency	13,637		13,034
Antibiotic	1,689		1,679
Pain Management	5,532		5,310
Obesity	1,310		547
Other	1,826		1,854
Total	$	35,294	$	28,878

Summary of certain of the Company's products which accounted for greater than 10% of net sales

	2012		2011
Product 1	39	%	45	%
Product 2	10	%	9	%
Product 3	10	%	—
Product 4	8	%	12	%

Summary of certain of the Company's customers which accounted for greater than 10% of net sales

	2012		2011
Customer A	17	%	21	%
Customer B	11	%	12	%
Customer C	10	%	9	%
Customer D	10	%	11	%